Paper36949472
BEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosis.
Schultz A and 13 others. Trials, 2023. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. BEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosis. Papers, record 36949472. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36949472
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- BEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosis.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cystic Fibrosis | Major topic |
| Adult | |
| Child | |
| Humans | |
| Anti-Bacterial Agents | |
| Bayes Theorem | |
| Forced Expiratory Volume | |
| Lung | |
| Prospective Studies | |
| Quality of Life | |
| Multicenter Studies as Topic | |
| Adaptive Clinical Trials as Topic |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| GNT1152376 | MRFF | PubMed |
Source PubMed
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28778919 | The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers. | Thorax | 2018 | https://conductscience.org/library/papers/28778919 | PubMed |
| 2 | 31483853 | Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. | Cochrane Database Syst Rev | 2019 | https://conductscience.org/library/papers/31483853 | PubMed |
| 3 | 16608383 | Getting it right: being smarter about clinical trials. | PLoS Med | 2006 | https://conductscience.org/library/papers/16608383 | PubMed |
| 4 | 25911223 | Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis. | Thorax | 2016 | https://conductscience.org/library/papers/25911223 | PubMed |
| 5 | 30376155 | Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. | Cochrane Database Syst Rev | 2018 | https://conductscience.org/library/papers/30376155 | PubMed |
| 6 | 28679092 | Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28679092 | PubMed |
| 7 | 34266854 | Variation in treatment preferences of pulmonary exacerbations among Australian and New Zealand cystic fibrosis physicians. | BMJ Open Respir Res | 2021 | https://conductscience.org/library/papers/34266854 | PubMed |
| 8 | 27440100 | SPIRIT 2013 Statement: defining standard protocol items for clinical trials. | Rev Panam Salud Publica | 2015 | https://conductscience.org/library/papers/27440100 | PubMed |
| 9 | 28460885 | Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations. | J Cyst Fibros | 2017 | https://conductscience.org/library/papers/28460885 | PubMed |
| 10 | 32571382 | Defining key design elements of registry-based randomised controlled trials: a scoping review. | Trials | 2020 | https://conductscience.org/library/papers/32571382 | PubMed |
| 11 | 28438499 | Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis. | J Cyst Fibros | 2017 | https://conductscience.org/library/papers/28438499 | PubMed |
| 12 | 24315208 | Lung clearance index: evidence for use in clinical trials in cystic fibrosis. | J Cyst Fibros | 2014 | https://conductscience.org/library/papers/24315208 | PubMed |
| 13 | 26595740 | Pulmonary Exacerbations in Children with Cystic Fibrosis. | Ann Am Thorac Soc | 2015 | https://conductscience.org/library/papers/26595740 | PubMed |
| 14 | 23734646 | Novel end points for clinical trials in young children with cystic fibrosis. | Expert Rev Respir Med | 2013 | https://conductscience.org/library/papers/23734646 | PubMed |
| 15 | 18090999 | Nested randomized trials in large cohorts and biobanks: studying the health effects of lifestyle factors. | Epidemiology | 2008 | https://conductscience.org/library/papers/18090999 | PubMed |
| 16 | 19481983 | Patient-reported respiratory symptoms in cystic fibrosis. | J Cyst Fibros | 2009 | https://conductscience.org/library/papers/19481983 | PubMed |
| 17 | 34469706 | A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment. | Am J Respir Crit Care Med | 2021 | https://conductscience.org/library/papers/34469706 | PubMed |
| 18 | 32800708 | Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatment. | J Cyst Fibros | 2021 | https://conductscience.org/library/papers/32800708 | PubMed |
| 19 | 10190914 | Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. | J Pediatr | 1999 | https://conductscience.org/library/papers/10190914 | PubMed |
| 20 | 31462747 | Adaptive platform trials: definition, design, conduct and reporting considerations. | Nat Rev Drug Discov | 2019 | https://conductscience.org/library/papers/31462747 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 39831540 | Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis. | Cochrane Database Syst Rev | 2025 | https://conductscience.org/library/papers/39831540 |
Source PubMed
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| RAB40B | 10966 | PubTator's text mining | https://conductscience.org/library/genes/10966 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36949472
GET https://conductscience.org/api/papers/v1/36949472/references?page=2